{"filing":{"accession_number":"0001171843-26-004605","cik":"0001581178","ticker":"EPRX","company_name":"EUPRAXIA PHARMACEUTICALS INC.","form":"6-K","filing_date":"2026-07-13","report_date":null,"primary_document":"f6k_071326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1581178/000117184326004605/f6k_071326.htm"},"events":[{"id":17601,"run_id":15768,"accession_number":"0001171843-26-004605","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The press release announces the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations, effective July 13, 2026, and the promotion of Dr. Alex Therien to Executive Vice President, Research \u0026 Development. While the release also discloses Amanda Malone's departure as Chief Scientific and Operating Officer, the principal disclosed action is the addition of experienced executive leadership to support the company's transition to late-stage development ahead of the Q4 2026 RESOLVE trial interim release. This is material to investors assessing management capability during a critical growth phase.","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-07-13","form":"6-K","submitted_at":null,"items":[{"id":16139,"accession_number":"0001171843-26-004605","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The press release announces the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations, effective July 13, 2026, and the promotion of Dr. Alex Therien to Executive Vice President, Research \u0026 Development. While the release also discloses Amanda Malone's departure as Chief Scientific and Operating Officer, the principal disclosed action is the addition of experienced executive leadership to support the company's transition to late-stage development ahead of the Q4 2026 RESOLVE trial interim release. This is material to investors assessing management capability during a critical growth phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:16:53.250395+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16139,"accession_number":"0001171843-26-004605","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The press release announces the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations, effective July 13, 2026, and the promotion of Dr. Alex Therien to Executive Vice President, Research \u0026 Development. While the release also discloses Amanda Malone's departure as Chief Scientific and Operating Officer, the principal disclosed action is the addition of experienced executive leadership to support the company's transition to late-stage development ahead of the Q4 2026 RESOLVE trial interim release. This is material to investors assessing management capability during a critical growth phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:16:53.250395+00:00","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-07-13"}]}